ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.-论文-万方医学网

第一作者： Christopher,Coyle

第一单位： MRC Clinical Trials Unit, UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK.

作者： Christopher,Coyle ^[1] ; Fay H,Cafferty ^[1] ; Samuel,Rowley ^[1] ; Mairead,MacKenzie ^[2] ; Lindy,Berkman ^[3] ; Sudeep,Gupta ^[4] ; C S,Pramesh ^[5] ; Duncan,Gilbert ^[6] ; Howard,Kynaston ^[7] ; David,Cameron ^[8] ; Richard H,Wilson ^[9] ; Alistair,Ring ^[10] ; Ruth E,Langley ^[11] ; Add-Aspirin investigators

作者单位： MRC Clinical Trials Unit, UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK. ^[1] Independent Cancer Patient Voices, 17 Woodbridge Street, London EC1R 0LL, UK. ^[2] NCRI Consumer Forum, Angel Building, 407 St John Street, London EC1V 4AD, UK. ^[3] Room No. 1109, 11th Floor, Homi Bhabha Block, Tata Memorial Centre/Hospital, Parel, Mumbai 400012, India. ^[4] Department of Surgical Oncology, Tata Memorial Centre, Dr Ernest Borges Marg, Parel, Mumbai 400012, India. ^[5] MRC Clinical Trials Unit, UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK; Sussex Cancer Centre, Royal Sussex County Hospital, Eastern Road, Brighton, Sussex BN2 5BE, UK. ^[6] Room 2F65, Block A2, Cardiff School of Medicine, Heath Park, Cardiff CF14 4XN, UK. ^[7] Edinburgh Cancer Research Centre, University of Edinburgh, Western General Hospital, Crewe Road South, EH4 2XR, UK. ^[8] Centre for Cancer Research and Cell Biology, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, Northern Ireland, UK. ^[9] The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK. ^[10] MRC Clinical Trials Unit, UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK. Electronic address: ruth.langley@ucl.ac.uk. ^[11]

医学主题词消炎药, 非甾类(Anti-Inflammatory Agents, Non-Steroidal);阿司匹林(Aspirin);乳腺肿瘤(Breast Neoplasms);化学疗法, 辅助(Chemotherapy, Adjuvant);结直肠肿瘤(Colorectal Neoplasms);无病生存(Disease-Free Survival);双盲法(Double-Blind Method);药物过敏(Drug Hypersensitivity);食管肿瘤(Esophageal Neoplasms);女(雌)性(Female);胃肠出血(Gastrointestinal Hemorrhage);人类(Humans);印度(India);颅内出血(Intracranial Hemorrhages);纵向研究(Longitudinal Studies);黄斑变性(Macular Degeneration);男(雄)性(Male);肿瘤复发, 局部(Neoplasm Recurrence, Local);肿瘤(Neoplasms);消化性溃疡(Peptic Ulcer);前列腺肿瘤(Prostatic Neoplasms);胃肿瘤(Stomach Neoplasms);存活率(Survival Rate);耳鸣(Tinnitus)

DOI 10.1016/j.cct.2016.10.004

PMID 27777129

发布时间 2025-05-30

检索历史清除

ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.

Contemporary clinical trials

相似文献

同项目论文

Contemporary clinical trials

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.

Contemporary clinical trials

相似文献

同项目论文

Contemporary clinical trials

相关期刊

检索历史清除